Full-Time

Associate Director

Commercial Data Management

 Otsuka Pharmaceutical

Otsuka Pharmaceutical

1,001-5,000 employees

Global pharmaceutical company developing medicines

Compensation Overview

$169.2k - $253k/yr

+ Incentive

Princeton, NJ, USA

In Person

Category
Data & Analytics (1)
Required Skills
Veeva
SQL
RDBMS
Salesforce
Data Governance
Requirements
  • Experience working within the pharmaceutical industry within data operations/data management environments.
  • Significant experience with Commercial third-party data assets, including Xponent Plantrak, DDD, HCOS, Claims Data, Specialty pharma, omnichannel data, Salesforce/Veeva (Call/Sample/Detail), etc.
  • Strong working knowledge of SQL, data warehousing concepts, dimensional/relational databases.
  • Demonstrated ability to manage ambiguity and work through day-to-day operational challenges.
  • Comfortable with translating both business concepts to technical terms and technical concepts to business terms.
  • Working knowledge of Clinical and R&D domains is a plus.
  • Experience supporting change efforts and enabling results through influence, persuasion and relationships.
  • Highest personal and professional integrity and strong work ethics.
  • Results orientation, willingness to commit to a direction and drive operations to completion.
  • Demonstrated ability to manage adversity and challenging situations.
  • Ability to develop cooperative and constructive working relationships.
  • Assesses quickly with a track record of getting up to speed and adding immediate value to new situations.
  • Ability to co-create and work collectively with key stakeholders.
  • Excellent oral and written communication skills, including the ability to organize, conceptually interpret and clearly communicate material developed collaboratively via the input of multiple parties.
  • Influencing and negotiation skills.
  • Up to 10% travel is required based upon business needs.
  • Bachelor’s degree
  • Minimum 8-10 years data related experience within the pharmaceutical industry
Responsibilities
  • Providing direction and synthesizing the needs of key stakeholders into clear requirements and execution plans.
  • Serve as a point of escalation for individual CDM activities and work closely with Dir, CDM and other DE roles to improve CDM processes.
  • Assume ownership for gathering metadata and other contextual information to catalog new data sources.
  • Work closely with the DE Data Quality & Standards capability to apply quality principals and best practices to individual data assets as appropriate.
  • Consistently keep up with industry data trends.
  • Support an enterprise wide CDM framework with emphasis on modifications to organizational behavior, policies and standards, guiding principles, metrics, related tools and data architecture.
  • Serve as a liaison between business, functional, and technology groups to ensure that data related business requirements are clearly defined, communicated and well understood and considered as part of operational prioritization and planning.
  • Define indicators of performance and quality metrics and ensure compliance with data related policies and standards for purchased data.
  • Work closely with the Data Scouting lead role/s to aid in informing requirements for new data assets and provide input into contracting as necessary.
  • Function as a knowledge base and resource to project teams.
  • Model and coach engagement best practices that enable thought partnership and engender a collaborative environment with robust debate; Furthering the partnership and impact of Data Enablement at Otsuka.
  • Foster a culture that embraces the strategic use of data into decision making enabling greater business outcomes.
  • Model the balance of innovation and intellectual curiosity with discipline and structure; Is a champion of value-add change and evolution and is able to inspire and motivate others.
Desired Qualifications
  • Masters in Computer Science, MIS, Information Management or related
  • Accountability for Results
  • Strategic Thinking & Problem Solving
  • Patient & Customer Centricity
  • Impactful Communication
  • Respectful Collaboration
  • Empowered Development
 Otsuka Pharmaceutical

Otsuka Pharmaceutical

View

Otsuka Pharmaceutical is a global health-focused company that develops and markets medicines and nutraceutical products. It creates pharmaceuticals like Abilify (aripiprazole), an antipsychotic, and consumer health brands such as Pocari Sweat, an ion-replacement drink. Its products work by medical mechanisms (Abilify modulates dopamine and serotonin receptors to treat psychiatric conditions) and by supporting hydration and electrolyte balance (Pocari Sweat). Otsuka differentiates itself through a long, international growth path from its roots as a Japanese chemical manufacturer, a balanced portfolio spanning prescription drugs and health beverages, and a philosophy of developing new products to improve health worldwide. Its goal is to deliver healthier outcomes for people around the world by expanding access to innovative medicines and health-related consumer products.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1921

Simplify Jobs

Simplify's Take

What believers are saying

  • Voyxact achieves 82.5% hematuria improvement in IgAN trial at 48 weeks.
  • Acquired Transcend Therapeutics for $700M to advance psychiatric MDMA analog.
  • Partnered Keio University on May 8, 2025, for psychedelics infrastructure.

What critics are saying

  • AbbVie acquires Gilgamesh bretisilocin for $1.2B, leapfrogging Otsuka psychedelics.
  • Voyxact confirmatory trial fails kidney preservation in 18-24 months.
  • Japanese regulations block psychedelics trials in 24-36 months.

What makes Otsuka Pharmaceutical unique

  • Pioneered IV solutions in 1946, becoming Japan's top supplier.
  • Launched Pocari Sweat ion drink and Abilify antipsychotic globally.
  • Focuses on carbostyril-based original drugs since 1980.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Otsuka Pharmaceutical who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Tuition Reimbursement

Student Loan Assistance

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Dealroom.co
Mar 27th, 2026
Transcend Therapeutics company information, funding & investors

Transcend Therapeutics, developing the next generation of psychoactive compounds for neuropsychiatry focused on patient access. Here you'll find information about their funding, investors and team.

Fierce Biotech
Mar 27th, 2026
Otsuka buys Transcend Therapeutics for $700M upfront in psychiatric drugs deal

Otsuka Pharmaceutical has acquired Transcend Therapeutics for $700 million upfront through its subsidiary Otsuka America, with potential milestone payments of up to $525 million. The deal gives Otsuka access to Transcend's MDMA analogue for psychiatric conditions currently in development.

The Associated Press
Mar 25th, 2026
Otsuka's Voyxact shows 82.5% hematuria improvement in IgA nephropathy trial at 48 weeks

Otsuka presented new Phase 3 VISIONARY trial data for VOYXACT (sibeprenlimab-szsi) in IgA nephropathy patients at the 2026 ISN World Congress of Nephrology. The analyses showed 82.5% of patients receiving sibeprenlimab achieved negative microscopic hematuria at week 48, compared with 52.6% on placebo. Median time to achieve hematuria negativity was nine weeks versus 24 weeks for placebo. VOYXACT, approved under accelerated approval in the US, is a monoclonal antibody that inhibits APRIL, a key driver in IgAN pathogenesis. Previously reported data showed the drug met its primary endpoint with a 51.2% placebo-adjusted reduction in proteinuria at nine months. The trial continues evaluating sibeprenlimab's effect on preserving kidney function over 24 months.

Business Wire
Mar 2nd, 2026
Paradise ultrasound renal denervation system now covered by insurance in Japan for resistant hypertension

Otsuka Medical Devices and Otsuka Pharmaceutical have launched the Paradise Ultrasound Renal Denervation system in Japan, with National Health Insurance coverage effective 1 March. The device, developed by US subsidiary Recor Medical, treats resistant hypertension by reducing sympathetic nerve overactivity surrounding renal arteries. The system targets patients whose blood pressure remains above target despite using three different antihypertensive medications, including a diuretic. This marks Japan's first ultrasound renal denervation treatment. The Paradise system received FDA approval in the US in November 2023. Under a co-promotion agreement, both Otsuka companies will leverage their cardiovascular and renal expertise to deliver the treatment according to guidelines established by Japanese medical societies. The system offers a new option for resistant hypertension patients at high risk of serious cardiovascular complications.

The Associated Press
Feb 6th, 2026
Sky Labs secures exclusive deal with Otsuka Pharmaceutical to launch ring-type blood pressure monitor in Japan

Sky Labs has signed an exclusive distribution agreement with Otsuka Pharmaceutical to launch its ring-type blood pressure monitor, CART BP pro, in Japan's hospital and clinic market. The deal follows an MoU signed in December 2024. CART BP pro uses photoplethysmography technology to measure blood pressure without a cuff, allowing comfortable monitoring during daily activities and sleep. The device has already achieved success in South Korea, with over 150,000 prescriptions across 1,700 medical institutions since its 2023 approval and national health insurance coverage in 2024. Japan's hypertension market includes approximately 43 million patients, with 29% failing to achieve blood pressure control and 33% unaware of their condition. Sky Labs will leverage Otsuka's distribution network and cardiovascular expertise to expand across Japanese healthcare facilities.